HDFC Pharma And Healthcare Fund
Sectoral-PharmaVery HighOPEN-ENDED
- NAV as on 9 Nov 2026
- ₹22.62+2.85%1 day
- Return since launch
- 29.2%
- 52-week range
- ₹16.36 — ₹22.10
- AUM
- ₹3,501 Cr
HDFC Pharma And Healthcare Fund is a Sectoral-Pharma equity fund from HDFC Mutual Fund with ₹3,501 Cr under management, launched in 2023. Over three years it has returned 25.8% a year, against 21.2% for its category. The expense ratio is 2.12% and the SEBI riskometer reading is Very High.
Performance
HDFC Pharma And Healthcare Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +31.0% against +19.9% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 39.6% | +18.8 pts | 20.8% | 29.1% |
| 2Y | 26.9% | +7.8 pts | 19.1% | 17.6% |
| 3Y | 25.8% | +4.5 pts | 21.2% | 16.0% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 8.9% | +0.5 pts | 8.4% | 8.5% |
| 3M | 5.3% | +1.6 pts | 3.7% | 3.7% |
| 6M | 17.7% | +3.7 pts | 14.0% | 13.6% |
| 1Y | 30.1% | +9.3 pts | 20.8% | 19.4% |
| 2Y | 18.2% | +7.4 pts | 10.8% | 9.5% |
| 3Y | 29.6% | +8.4 pts | 21.2% | 20.0% |
Since launch (14 Sep 2023): 29.2%
Calendar-year returns
Category average49.8%
1.2%
Show as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | 1.2% | +3.3 pts | -2.0% |
| 2024 | 49.8% | +8.9 pts | 40.9% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.11%
Expense ratio as on 4 Nov 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 1.64%
- Brokerage
- 0.04%
- Transaction charges
- 0.01%
- Statutory levies
- 0.42%
- Exit load
- Exit load of 1%, if redeemed within 30 days.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- BSE Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Very High
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
| Ratio | Fund | Category avg | Read as |
|---|---|---|---|
| Alpha | 5.17 | 0.57 | Return earned above what the benchmark alone would have given. Higher is better. |
| Beta | 0.97 | 0.93 | How hard the fund moves when the market moves. Under 1 is steadier than the market. |
| Sharpe | 1.33 | 1.04 | Return earned for each unit of total risk taken. Higher is better. |
| Sortino | 2.04 | 1.76 | Return earned for each unit of downside risk. Higher is better. |
| Std. deviation | 16.11 | 15.49 | How widely monthly returns have varied around their own average. Lower is steadier. |
| Average of 4 category peers | |||
Portfolio
HDFC Pharma And Healthcare Fund portfolio
Portfolio as of 30 Sep 2026
Asset allocation
- Equity96.8%
- Other3.2%
Market cap split
- Large30.1%
- Mid31.1%
- Small38.8%
- P/E
- 48.47
- P/B
- 6.27
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Divi's Laboratories Ltd. | Healthcare | 9.39% | ₹329 Cr | +7.16% | +8.20% | +7.76% |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 8.28% | ₹290 Cr | +9.96% | +10.20% | +10.47% |
| Alkem Laboratories Ltd. | Healthcare | 4.64% | ₹163 Cr | +4.00% | +5.99% | +5.94% |
| Cipla Ltd. | Healthcare | 4.15% | ₹145 Cr | +5.19% | — | +4.32% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 3.69% | ₹129 Cr | — | — | — |
| Torrent Pharmaceuticals Ltd. | Healthcare | 3.65% | ₹128 Cr | — | +2.34% | +3.81% |
| Max Healthcare Institute Ltd. | Healthcare | 3.61% | ₹126 Cr | +5.57% | +5.96% | +4.66% |
| Aster DM Quality Care Ltd. | Healthcare | 3.56% | ₹125 Cr | +5.05% | +5.70% | +3.55% |
| Lupin Ltd. | Healthcare | 3.55% | ₹124 Cr | +5.26% | +6.65% | +6.84% |
| Neuland Laboratories Ltd. | Healthcare | 3.24% | ₹114 Cr | +2.93% | +1.54% | — |
| Others | Others | 3.23% | ₹113 Cr | -1.14% | -1.26% | -0.12% |
| Shilpa Medicare Ltd. | Healthcare | 3.23% | ₹113 Cr | +2.48% | +1.91% | — |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 3.19% | ₹112 Cr | +1.04% | — | — |
| Acutaas Chemicals Ltd. | Healthcare | 3.18% | ₹111 Cr | +4.58% | +4.39% | +2.31% |
| Anthem Biosciences Ltd. | Healthcare | 3.17% | ₹111 Cr | +3.81% | +4.29% | +3.26% |
| Ipca Laboratories Ltd. | Healthcare | 2.98% | ₹104 Cr | +3.53% | +5.16% | +4.50% |
| Global Health Ltd. | Healthcare | 2.72% | ₹95.30 Cr | +3.08% | +1.88% | — |
| Rubicon Research Ltd. | Healthcare | 2.52% | ₹88.16 Cr | +1.70% | +1.24% | — |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 2.10% | ₹73.50 Cr | +3.07% | +3.10% | +3.64% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 2.09% | ₹73.05 Cr | +2.88% | +6.78% | +6.93% |
| Molbio Diagnostics Ltd. | Healthcare | 2.01% | ₹70.42 Cr | — | — | — |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 2.00% | ₹70.17 Cr | +2.53% | +2.13% | +2.45% |
| Zydus Lifesciences Ltd. | Healthcare | 1.82% | ₹63.78 Cr | +2.34% | — | — |
| Gland Pharma Ltd. | Healthcare | 1.78% | ₹62.32 Cr | +1.20% | +1.07% | +2.12% |
| Wockhardt Ltd. | Healthcare | 1.71% | ₹59.95 Cr | +2.11% | +1.54% | +2.07% |
| Jupiter Life Line Hospitals Ltd. | Healthcare | 1.68% | ₹58.95 Cr | +0.27% | — | — |
| Metropolis Healthcare Ltd. | Healthcare | 1.67% | ₹58.58 Cr | +2.24% | +2.37% | +2.64% |
| Sai Life Sciences Ltd. | Healthcare | 1.58% | ₹55.18 Cr | +1.71% | +2.09% | +1.67% |
| Biocon Ltd. | Healthcare | 1.47% | ₹51.49 Cr | +1.17% | — | — |
| Symbiotec Pharmalab Ltd. | Healthcare | 1.36% | ₹47.64 Cr | — | — | — |
| Thyrocare Technologies Ltd. | Healthcare | 1.10% | ₹38.41 Cr | +1.51% | +1.27% | — |
| CORONA Remedies Ltd. | Healthcare | 1.04% | ₹36.29 Cr | +1.31% | — | — |
| Entero Healthcare Solutions Ltd. | Healthcare | 1.01% | ₹35.37 Cr | — | — | — |
| Jubilant Pharmova Ltd. | Healthcare | 0.93% | ₹32.67 Cr | +1.18% | +1.31% | +1.81% |
| Eris Lifesciences Ltd. | Healthcare | 0.92% | ₹32.34 Cr | +1.49% | +2.24% | +3.19% |
| Novartis India Ltd. | Healthcare | 0.55% | ₹19.31 Cr | +0.53% | — | — |
| Bajaj Healthcare Ltd. | Healthcare | 0.53% | ₹18.62 Cr | +0.77% | +0.83% | +1.34% |
| Laxmi Dental Ltd. | Healthcare | 0.35% | ₹12.34 Cr | +0.56% | +0.52% | +1.11% |
| Cohance Lifesciences Ltd. | Healthcare | 0.32% | ₹11.10 Cr | +0.44% | — | +1.99% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Fortis Healthcare Ltd. | 2.37% | 0.00% | -2.37% |
| Apollo Hospitals Enterprise Ltd. | 1.39% | 3.69% | +2.30% |
| Alkem Laboratories Ltd. | 3.06% | 4.64% | +1.58% |
| Dr. Reddy's Laboratories Ltd. | 1.90% | 3.19% | +1.29% |
| Others | -0.25% | -1.44% | -1.19% |
| Ajanta Pharma Ltd. | 1.18% | 0.00% | -1.18% |
| Entero Healthcare Solutions Ltd. | 0.00% | 1.01% | +1.01% |
| Gland Pharma Ltd. | 1.09% | 1.78% | +0.69% |
| Sun Pharmaceutical Industries Ltd. | 8.94% | 8.28% | -0.66% |
| Lupin Ltd. | 4.04% | 3.55% | -0.49% |
| Neuland Laboratories Ltd. | 3.70% | 3.24% | -0.46% |
| Max Healthcare Institute Ltd. | 4.06% | 3.61% | -0.45% |
| Torrent Pharmaceuticals Ltd. | 4.08% | 3.65% | -0.43% |
| Anthem Biosciences Ltd. | 3.48% | 3.17% | -0.31% |
| Rubicon Research Ltd. | 2.82% | 2.52% | -0.30% |
| Aster DM Quality Care Ltd. | 3.84% | 3.56% | -0.28% |
| Biocon Ltd. | 1.73% | 1.47% | -0.26% |
| Jupiter Life Line Hospitals Ltd. | 1.94% | 1.68% | -0.26% |
| Glenmark Pharmaceuticals Ltd. | 2.34% | 2.09% | -0.25% |
| Ipca Laboratories Ltd. | 3.23% | 2.98% | -0.25% |
| Vijaya Diagnostic Centre Ltd. | 2.24% | 2.00% | -0.24% |
| Molbio Diagnostics Ltd. | 1.77% | 2.01% | +0.24% |
| Metropolis Healthcare Ltd. | 1.90% | 1.67% | -0.23% |
| Cipla Ltd. | 3.94% | 4.15% | +0.21% |
| Thyrocare Technologies Ltd. | 1.31% | 1.10% | -0.21% |
| Symbiotec Pharmalab Ltd. | 1.21% | 1.36% | +0.15% |
| Krishna Institute of Medical Sciences Ltd | 2.25% | 2.10% | -0.15% |
| Divi's Laboratories Ltd. | 9.54% | 9.39% | -0.15% |
| Eris Lifesciences Ltd. | 1.06% | 0.92% | -0.14% |
| Global Health Ltd. | 2.85% | 2.72% | -0.13% |
| Shilpa Medicare Ltd. | 3.10% | 3.23% | +0.13% |
| Zydus Lifesciences Ltd. | 1.93% | 1.82% | -0.11% |
| Wockhardt Ltd. | 1.61% | 1.71% | +0.10% |
| Jubilant Pharmova Ltd. | 0.85% | 0.93% | +0.08% |
| Novartis India Ltd. | 0.47% | 0.55% | +0.08% |
| Acutaas Chemicals Ltd. | 3.24% | 3.18% | -0.06% |
| Bajaj Healthcare Ltd. | 0.57% | 0.53% | -0.04% |
| CORONA Remedies Ltd. | 1.07% | 1.04% | -0.03% |
| Laxmi Dental Ltd. | 0.38% | 0.35% | -0.03% |
| Cohance Lifesciences Ltd. | 0.34% | 0.32% | -0.02% |
| Sai Life Sciences Ltd. | 1.60% | 1.58% | -0.02% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹2,792 Cr | 1.83% | 35.7% | 19.6% | 21.6% |
 SBI Healthcare Opportunities Fund | ₹6,067 Cr | 1.98% | 35.0% | 19.9% | 22.6% |
 Mirae Asset Healthcare Fund | ₹3,494 Cr | 2.01% | 37.3% | 20.2% | 21.1% |
 UTI Healthcare Fund | ₹1,430 Cr | 2.21% | 30.6% | 18.4% | 21.1% |
 ICICI Prudential Nifty Pharma Index Fund | ₹177 Cr | 1.13% | 39.9% | 19.9% | — |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Fund managers
- Nikhil MathurMr. Mathur has done B.Tech and PGDM in FinancePrior to joining HDFC Mutual Fund, he has worked with Ambit Capital, Goldman Sachs, Deloitte India and EY
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
₹
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months17.68% absolute | ₹60,000 | ₹70,608 | 17.68% | |
| 1 year30.12% annualised | ₹1,20,000 | ₹1,41,498 | 17.92% | |
| 3 years29.65% annualised | ₹3,60,000 | ₹5,83,821 | 62.17% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.
What is the NAV of HDFC Pharma And Healthcare Fund?
The NAV of HDFC Pharma And Healthcare Fund is ₹22.62 as on 9 Nov 2026.
What is the expense ratio of HDFC Pharma And Healthcare Fund?
The expense ratio of HDFC Pharma And Healthcare Fund is 2.12% per year.
What is the minimum SIP amount for HDFC Pharma And Healthcare Fund?
You can start a SIP in HDFC Pharma And Healthcare Fund with ₹3,000 a month.
Is there a lock-in or exit load on HDFC Pharma And Healthcare Fund?
Lock-in: None. Exit load: Exit load of 1%, if redeemed within 30 days..
How risky is HDFC Pharma And Healthcare Fund?
HDFC Pharma And Healthcare Fund is rated Very High on the SEBI riskometer and belongs to the Sectoral-Pharma category.
Which fund house manages HDFC Pharma And Healthcare Fund?
HDFC Pharma And Healthcare Fund is managed by HDFC Mutual Fund, which runs 86 schemes with ₹9,96,954 Cr under management.